SARS-CoV-2 S1-RBD IgG titers before and after third heterologous booster vaccination with Moderna COVID-19 vaccine in hemodialysis patients

DOI Web Site Web Site 14 References

Bibliographic Information

Other Title
  • 血液透析患者におけるモデルナ社製COVID-19ワクチン3回目異種ブースター接種前後のSARS-CoV-2 S1-RBD IgG抗体価の検討
  • ケツエキ トウセキ カンジャ ニ オケル モデルナシャセイ COVID-19 ワクチン 3カイメ イシュ ブースター セッシュ ゼンゴ ノ SARS-CoV-2 S1-RBD IgG コウタイカ ノ ケントウ

Search this article

Abstract

<p>We measured Abbottʼs S1-RBD IgG antibody titers before and after the third dose of Modernaʼs COVID-19 vaccine in hemodialysis (HD) patients, and examined factors affecting antibody titers. We used Pfizerʼs BNT162b2 (Pfizer) until the second vaccination, and Modernaʼs mRNA-1273 (Moderna) for the third vaccination 6 months after the second vaccination. Antibody titers increased markedly from a median of 275 (149-571) AU/mL before vaccination to 29,737 (14,984-46,185) AU/mL (108.1-fold) one month after vaccination. Multiple regression analysis showed that post-immunization antibody titers were lower in steroid-naive patients, and were also lower in patients with a lower BMI with the exception of those with a BMI of 30 or higher. The results suggest that hemodialysis patients who show emaciation or take steroids need to take more care regarding infection protection after vaccination.</p>

Journal

References(14)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top